Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Multiple Sclerosis

  Free Subscription


2 Acta Neuropathol
2 Arch Phys Med Rehabil
1 BMC Neurol
1 Brain
1 Eur Neurol
2 J Neuroimmunol
1 J Neurol Neurosurg Psychiatry
1 J Neurol Sci
9 Mult Scler
1 N Engl J Med
1 Neurologia
1 Neurology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Neuropathol

  1. PICON C, Jayaraman A, James R, Beck C, et al
    Neuron-specific activation of necroptosis signaling in multiple sclerosis cortical grey matter.
    Acta Neuropathol. 2021 Feb 10. pii: 10.1007/s00401-021-02274.
    PubMed         Abstract available

  2. BELTRAN E, Paunovic M, Gebert D, Cesur E, et al
    Correction to: Archeological neuroimmunology: resurrection of a pathogenic immune response from a historical case sheds light on human autoimmune encephalomyelitis and multiple sclerosis.
    Acta Neuropathol. 2021 Feb 9. pii: 10.1007/s00401-021-02267.

    Arch Phys Med Rehabil

  3. ANDREU-CARAVACA L, Ramos-Campo DJ, Chung LH, Rubio-Arias JA, et al
    Dosage and effectiveness of aerobic training on cardiorespiratory fitness, functional capacity, balance, and fatigue in people with Multiple Sclerosis: a systematic review and meta-analysis.
    Arch Phys Med Rehabil. 2021 Feb 7. pii: S0003-9993(21)00148.
    PubMed         Abstract available

  4. SILVEIRA SL, Huynh T, Kidwell A, Bahmani DS, et al
    Behavior Change Techniques in Physical Activity Interventions for Multiple Sclerosis.
    Arch Phys Med Rehabil. 2021 Feb 4. pii: S0003-9993(21)00139.
    PubMed         Abstract available

    BMC Neurol

  5. PATT N, Kool J, Hersche R, Oberste M, et al
    High-intensity interval training and energy management education, compared with moderate continuous training and progressive muscle relaxation, for improving health-related quality of life in persons with multiple sclerosis: study protocol of a random
    BMC Neurol. 2021;21:65.
    PubMed         Abstract available


    Neuregulin therapy for multiple sclerosis: an each-way bet?
    Brain. 2021;144:6-8.

    Eur Neurol

  7. MCKENNA MC, Al-Hinai M, Bradley D, Doran E, et al
    Patients' Experiences of Remote Neurology Consultations during the COVID-19 Pandemic.
    Eur Neurol. 2020;83:622-625.
    PubMed         Abstract available

    J Neuroimmunol

  8. KHADEMI B, Khorrami M, Ayromlou H, Rikhtegar R, et al
    An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577507.
    PubMed         Abstract available

  9. ONMAZ DE, Isik SMT, Abusoglu S, Ekmekci AH, et al
    Serum ADMA levels were positively correlated with EDSS scores in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577497.
    PubMed         Abstract available

    J Neurol Neurosurg Psychiatry

    It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease.
    J Neurol Neurosurg Psychiatry. 2021 Feb 9. pii: jnnp-2020-325684.

    J Neurol Sci

  11. KOVVURU S, Nalleballe K, Onteddu SR, Sharma R, et al
    Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic.
    J Neurol Sci. 2021;420:117230.
    PubMed         Abstract available

    Mult Scler

  12. BRUIJSTENS AL, Blok KM, Smolders J, Wokke BH, et al
    Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
    Mult Scler. 2020 May 14:1352458520921367. doi: 10.1177/1352458520921367.

  13. PILUTTI LA, Fakolade A
    Rehabilitation should be prescribed acutely in motor relapses - Commentary.
    Mult Scler. 2020;26:1825-1827.

  14. COETZEE T, Thompson AJ
    Atlas of MS 2020: Informing global policy change.
    Mult Scler. 2020;26:1807-1808.

  15. DAS J, Snowden JA, Burman J, Freedman MS, et al
    Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520985238. doi: 10.1177/1352458520985238.
    PubMed         Abstract available

  16. KRASNIUK S, Classen S, Morrow SA, Alvarez L, et al
    Clinical predictors of driving simulator performance in drivers with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458521992507. doi: 10.1177/1352458521992507.
    PubMed         Abstract available

  17. VELDKAMP R, Kalron A, Baert I, Hamalainen P, et al
    Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive-motor interference in persons with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520986960. doi: 10.1177/1352458520986960.
    PubMed         Abstract available

  18. MIDAGLIA L, Sastre-Garriga J, Pappolla A, Quibus L, et al
    The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.
    Mult Scler. 2021 Feb 10:1352458520988148. doi: 10.1177/1352458520988148.
    PubMed         Abstract available

  19. BELVISI D, Canevelli M, Baione V, Buscarinu MC, et al
    Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.
    Mult Scler. 2021 Feb 10:1352458520987541. doi: 10.1177/1352458520987541.
    PubMed         Abstract available

  20. RICIGLIANO VA, Tonietto M, Palladino R, Poirion E, et al
    Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study.
    Mult Scler. 2020 Jun 17:1352458520921362. doi: 10.1177/1352458520921362.
    PubMed         Abstract available

    N Engl J Med

    Regulatory T Cells in Multiple Sclerosis.
    N Engl J Med. 2021;384:578-580.


  22. VAZQUEZ-MARRUFO M, Sarrias-Arrabal E, Garcia-Torres M, Martin-Clemente R, et al
    A systematic review of the application of machine-learning algorithms in multiple sclerosis.
    Neurologia. 2021 Feb 3. pii: S0213-4853(20)30431.
    PubMed         Abstract available


  23. NAISMITH RT, Bermel RA, Coffey CS, Goodman AD, et al
    Effects of ibudilast on MRI measures in the phase 2 SPRINT-MS study.
    Neurology. 2020 Dec 2. pii: WNL.0000000000011314.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.